ID   HCC827 ER3
SY   ER3
DR   cancercelllines; CVCL_EJ09
DR   Cosmic; 1716794
DR   GEO; GSM938758
DR   GEO; GSM938759
DR   GEO; GSM938760
DR   GEO; GSM938761
DR   GEO; GSM938762
DR   GEO; GSM938763
DR   Wikidata; Q54881785
RX   PubMed=22751098;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:114785; Erlotinib.
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2236_2250del15); ClinVar=VCV000177620; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Homozygous (from parent cell line).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2063 ! HCC827
SX   Female
AG   39Y
CA   Cancer cell line
DT   Created: 26-09-16; Last updated: 05-10-23; Version: 12
RX   PubMed=22751098; DOI=10.1038/ng.2330;
RA   Zhang Z.-F., Lee J.C., Lin L.-P., Olivas V., Au V., LaFramboise T.,
RA   Abdel-Rahman M., Wang X.-Q., Levine A.D., Rho J.K., Choi Y.J.,
RA   Choi C.-M., Kim S.-W., Jang S.J., Park Y.S., Kim W.S., Lee D.H.,
RA   Lee J.-S., Miller V.A., Arcila M.E., Ladanyi M., Moonsamy P.,
RA   Sawyers C.L., Boggon T.J., Ma P.C., Costa C., Taron M., Rosell R.,
RA   Halmos B., Bivona T.G.;
RT   "Activation of the AXL kinase causes resistance to EGFR-targeted
RT   therapy in lung cancer.";
RL   Nat. Genet. 44:852-860(2012).